Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and effectiveness of immunotherapy
(checkpoint inhibitor therapy) in advanced bladder cancer when given intermittently. An
unanswered question with the use of CPI (checkpoint inhibitor) is the duration of therapy
required for optimal clinical benefit. In the absence of progressive disease or unacceptable
toxicities, there are currently no specified criteria for treatment discontinuation.
Strategies to reduce toxicity and maximize benefit require investigation. Thus, novel dosing
schedules, early discontinuation considerations, and biomarkers of response are needed to
identify patients who can sustain disease regression while off of therapy.